deltatrials
Terminated PHASE2 INTERVENTIONAL 1-arm NCT01488318

Cetuximab and Dasatinib in Recurrent Squamous Cell Carcinoma

Phase II Trial of Cetuximab and Dasatinib in Patients With Cetuximab-resistant, Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck and Low Serum IL-6

Sponsor: Bristol-Myers Squibb

Conditions Squamous Cell Carcinoma Of The Head And Neck
Interventions Cetuximab Dasatinib
Updated 9 times since 2017 Last updated: Dec 7, 2017 Started: Sep 30, 2011 Primary completion: Jan 31, 2016 Completion: Aug 31, 2016
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

PI leaving the institution

Other terminated trials from Bristol-Myers Squibb

See all terminations from Bristol-Myers Squibb

This PHASE2 trial investigates Squamous Cell Carcinoma Of The Head And Neck and is currently terminated or withdrawn. Bristol-Myers Squibb leads this study, which shows 9 recorded versions since 2011 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jan 2018 · 11 months · monthly snapshotTerminated~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Dec 2022 · 23 months · monthly snapshotTerminated~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotTerminated~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – present · 22 months · monthly snapshotTerminated

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE2

  5. Jan 2021 — Dec 2022 [monthly]

    Terminated PHASE2

▶ Show 4 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  2. Jan 2018 — Jun 2018 [monthly]

    Terminated PHASE2

  3. Feb 2017 — Jan 2018 [monthly]

    Terminated PHASE2

  4. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

Sep 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Julie E. Bauman, MD, MPH
Data source: University of Pittsburgh

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations